Prime Medicine wins spat with Beam Therapeutics over AATD candidate

Prime Medicine wins arbitration vs Beam Therapeutics, plans FDA IND filing for genetic liver disease treatment. $PRME stock rises 12%. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…

Nicole DeFeudis · 2026-07-08

Prime Medicine is headed for the clinic after winning a dispute with Beam Therapeutics, another gene editing biotech with roots in the same lab. Arbitrators determined that a 2019 contract between the companies doesn't preclude ...

Source: Endpoints News